Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Alex Denner

Novelion Therapeutics Inc. (NASDAQ:NVLN): Alex Denner’s Sarissa Capital Management filed an amended 13D.

You can check out Sarissa Capital Management’s latest holdings and filings here.

Please follow Sarissa Capital Management (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Sarissa Capital Management or update its stock holdings.

Alex Denner
Alex Denner
Sarissa Capital Management

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Sarissa Capital Management 8 1,934,296 10 1,934,296 1,934,296 9.86%
Alexander J. Denner, Ph.D 8 1,934,296 10 1,934,296 1,934,296 9.86%
Sarissa Capital Offshore Master Fund 1,316,953 9 1,316,953 11 1,316,953 6.8%
Sarissa Capital Catapult Fund 617,343 9 617,343 11 617,343 3.3%
Alex Denner
Alex Denner
Sarissa Capital Management

Page 1 of 9 – SEC Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

 

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

Novelion
Therapeutics Inc.

(Name of Issuer)

 

Common Stock, without par value

(Title of Class of Securities)

 

67001K202

(CUSIP Number)

 

Mark DiPaolo

General Counsel

Sarissa Capital Management LP

660 Steamboat Road

Greenwich, CT 06830

203-302-2330

With a copy to:

Todd E. Mason

Thompson Hine
LLP

335 Madison
Avenue

12th Floor

New York, New York 10017-4611

(212)
344-5680

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

 

 

March 15, 2018

(Date of Event which Requires Filing of this Statement)

 

 

If
the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this
Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ¨

Note: Schedules
filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for
other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).

Follow Novelion Therapeutics Inc. (NASDAQ:NVLN)
Trade (NASDAQ:NVLN) Now!
Loading...